Key Takeaways
- Amsterdam’s Enterprise Chamber rejected shareholders’ request for an investigation into Philips’ management of the recall.
- The court found insufficient grounds to question the company’s handling of information and internal oversight based on the evidence reviewed.
- The decision does not determine whether investors are entitled to compensation for losses linked to the recall.
Philips Wins Dutch Court Ruling as Shareholders’ Recall Inquiry Request Is Rejected
Philips has secured a significant legal outcome in the Netherlands, but the decision does not close every dispute surrounding its sleep-apnea device recall. On October 10, 2026, Amsterdam’s Enterprise Chamber rejected shareholders’ request for a formal investigation into the company’s management and disclosures.
Why Shareholders Sought an Investigation
The case relates to Philips Respironics’ 2021 global recall of certain sleep-apnea and respiratory devices. The machines contained polyester-based polyurethane foam that could degrade and potentially expose users to harmful particles or chemicals.
The Dutch investors’ association VEB and other shareholders argued that Philips identified the risks too late, failed to intervene promptly at its US subsidiary and did not adequately inform investors. They also questioned the oversight exercised by the company’s supervisory board.
What the Court Decided
After reviewing extensive documentation and internal records, the court found insufficient grounds to order the requested investigation. It said the evidence did not indicate that Philips’ executive and supervisory boards received reliable information about the health risks too late.
The court also found no sufficient reason to conclude that Philips should have intervened earlier at Respironics or that its public disclosures about the recall were late, incorrect or misleading.
However, the ruling has a defined scope. The court was deciding whether there were justified grounds to investigate the company’s management, not whether mistakes occurred at the device manufacturer or whether investors should receive compensation.
What Happens Next?
The recall has generated legal and regulatory proceedings in several jurisdictions. Philips continues to publish updates on its remediation programme and related litigation, meaning the Dutch decision should not be interpreted as ending every matter connected with the recall.
TwikUp’s Perspective
The decision highlights an important distinction in corporate litigation: rejecting a request for an investigation is not the same as resolving every question of liability. Investors assessing Philips should distinguish this specific Dutch ruling from separate proceedings, settlement arrangements and regulatory obligations.
The wider lesson for listed companies is that internal risk controls and timely disclosure remain central to investor confidence, particularly when product safety issues can affect both customers and shareholders.